JNK pathway as therapeutic target to prevent degeneration in the central nervous system

Adv Exp Med Biol. 2006:588:145-55. doi: 10.1007/978-0-387-34817-9_13.

Abstract

JNKs (c-Jun N- terminal kinases) are important transducing enzymes involved in many faces of cellular regulation such as gene expression, cell proliferation and programmed cell death. The activation of JNK pathway is critical for naturally occurring neuronal death during development as well as for pathological death of adult brain following different insults. In particular, JNKs play an important role in excitotoxicity and all related phenomena. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies have begun to see JNK as the appropriate target for prevent cell loss. We used a specific JNK inhibitor, the cell permeable peptide D-JNKI1, to block JNK action in neuronal death following excitotoxicity in vitro and cerebral ischemia in vivo. Here we review our recent findings and we discuss the possibility of using D-JNKI1 as a therapeutic agent to prevent cell loss in the central nervous system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Central Nervous System / physiology*
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Humans
  • Ischemia / pathology
  • MAP Kinase Kinase 4 / metabolism
  • MAP Kinase Kinase 4 / physiology*
  • Mice
  • Nerve Degeneration / pathology*
  • Nerve Degeneration / therapy*
  • Neurodegenerative Diseases / pathology*
  • Neurodegenerative Diseases / therapy*
  • Neurons / metabolism
  • Peptides / chemistry
  • Peptides / pharmacology
  • Rats

Substances

  • Enzyme Inhibitors
  • Peptides
  • MAP Kinase Kinase 4
  • D-JNKI-1